William Blair analyst Matt Larew has maintained their bullish stance on TWST stock, giving a Buy rating on November 3.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Matt Larew has given his Buy rating due to a combination of factors including Twist Bioscience’s recent financial performance and future growth potential. The company reported a top-line beat with significant year-over-year revenue growth in its SynBio, NGS, and Biopharma segments. Although the gross margin and adjusted EBITDA were slightly below expectations, management remains committed to reaching adjusted EBITDA breakeven by the fourth quarter of 2026.
Additionally, Twist Bioscience’s fiscal 2026 guidance suggests robust revenue growth and an improvement in gross margin, despite being slightly below consensus expectations. The decision to combine the SynBio and Biopharma segments into a single reporting segment is seen as a strategic move to streamline operations. Furthermore, the stock is currently trading at a lower multiple compared to its high-growth life science tools peers, indicating potential upside. These elements collectively contribute to the positive outlook and the Buy rating from Matt Larew.
In another report released on November 3, Stephens also initiated coverage with a Buy rating on the stock with a $41.00 price target.